{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5961","upperLimit":"0.9102","value":"0.7826"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Completion of 4 cycles of CT + GB- completion of a cycle will be defined as receiving both carboplatin/paclitaxel and taking ≥75% of the doses of GB for the cycle.","dispersionType":"90% Confidence Interval","groups":[{"description":"Galunisertib: Galunisertib 150mg po BID day 4-17\n\nPaclitaxel: Paclitaxel 175 mg/m2 over 3 hours\n\nCarboplatin: IV day 1 Carboplatin AUC 6\\* over 1 hour (or 5\\* if prior radiation therapy)","id":"OG000","title":"Paclitaxel/Carboplatin + Galunisertib"}],"paramType":"NUMBER","populationDescription":"Evaluable patients will be defined as patients who receive at least four cycles of study treatment.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Proportion of Patients With Completion of 4 Cycles of CT + GB","type":"PRIMARY","unitOfMeasure":"proportion of patients"}